SCHEMBL184997

SCHEMBL184997

O=C(O)C(Oc1ccc(Cl)cc1F)c1ccc(S(=O)(=O)N2CCOCC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.63
PPARA Q07869 2/20 0.63
GCK P35557 2/20 0.51
ALDH1A1 P00352 2/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.46
TP53 P04637 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
TSHR P16473 1/20 0.46
CNR1 P21554 1/20 0.46
GPR35 Q9HC97 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46
NPC1 O15118 2/20 0.45
KDM4E B2RXH2 1/20 0.45
APEX1 P27695 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL184524 0.90 GCK (0.61) PPARGPPARAGCKALDH1A1KMT2A
SCHEMBL184978 0.90 PPARG (0.65) PPARGPPARAGCKALDH1A1MEN1
SCHEMBL185301 0.83 KMT2A (0.61) ALDH1A1MEN1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL3772579 0.82 GCK (0.58) GCKALDH1A1MEN1KMT2ATP53
SCHEMBL184580 0.82 GCK (0.58) GCKALDH1A1SMN1; SMN2TSHRKDM4E
SCHEMBL184988 0.80 GCK (0.60) PPARGPPARAGCKKMT2AL3MBTL1
SCHEMBL185307 0.80 GCK (0.58) PPARGPPARAGCKKMT2ATSHR
SCHEMBL184805 0.80 GCK (0.77) GCKALDH1A1MEN1KMT2APTGDR2
SCHEMBL184698 0.79 GCK (0.61) PPARGPPARAGCKALDH1A1MEN1
SCHEMBL11997719 0.79 GCK (0.58) GCKALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2402327-B1 Acetamide compounds as glucokinase activators, their process and medicinal applications IMPETIS BIOSCIENCES LTD (IN) 2018-03-07 EP disclosed
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 US disclosed
EP-2402327-A1 Acetamide compounds as glucokinase activators, their process and medicinal applications Advinus Therapeutics Private Limited (IN) 2012-01-04 EP disclosed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION GCK, GCKR, ALDOA PPARG 329/4885PPARA 289/4885GCK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.